Limonin, a novel AMPK activator, protects against LPS-induced acute lung injury

AMP-activated protein kinase (AMPK) activation plays crucial roles in the treatment of many oxidative stressand inflammation-induced diseases, including acute lung injury (ALI). Limonin is a naturally occurring tetracyclic triterpenoid extracted from the plants of Rutaceae and Meliaceae. Limonin also serves as an AMPK activator with anti-inflammatory and anti-oxidation effects. However, the potential beneficial effects of limonin on ALI and the possible mechanisms have never been disclosed till now. Here, the effects of limonin on lipopolysaccharide (LPS)-induced ALI in C57 BL/6 mice, plus bone marrow-derived macrophages (BMDM) stimulated with LPS to induce in vitro ALI model were investigated. Limonin significantly improved pulmonary function and alleviated lung pathological injury in LPS-induced mice. Meanwhile, limonin also markedly decreased inflammation and oxidative stress in lung tissues from LPS-treated mice. In vitro experiments also unveiled that limonin could decrease inflammation and oxidative stress in LPS-induced BMDM in a concentration-dependent manner. Mechanically, limonin could promote the activation of AMPKa and upregulate the expression of nuclear factor erythroid 2-related factor 2 (NRF2) in lung tissues and BMDM. Pharmacological inhibition of AMPKa by Compound C or AMPKa knockout could abolish the pulmonary protection from limonin during ALI. In conclusion, limonin mediates the activation of AMPKa/NRF2 pathway, providing an attractive therapeutic target for ALI in the future.

Automated summary

Limonin, a naturally occurring tetracyclic triterpenoid, can activate the AMP-activated protein kinase (AMPK)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway, thereby improving inflammation and oxidative stress caused by acute lung injury (ALI).